TrimRx's Blog

Tirzepatide shows promise in reducing alcohol cravings through GLP-1 receptor mechanisms, with emerging clinical evidence supporting AUD treatment

Tirzepatide shows promise for smoking cessation through dopamine pathway modulation and craving reduction mechanisms beyond weight loss alone.

Tirzepatide does not directly cause gambling addiction, but GLP-1 agonists may alter dopamine pathways in susceptible individuals — here’s what the

Tirzepatide doesn’t directly cause social anxiety, but weight loss transitions and metabolic shifts can amplify existing concerns. What patients need to

Tirzepatide may trigger compulsive shopping in some patients through dopamine pathway changes. Research shows GLP-1 medications can alter reward-seeking

Ozempic hair loss affects 3–5% of patients during rapid weight reduction. Learn the mechanism, timeline, prevention strategies, and when regrowth occurs.

Weight loss plateaus on Ozempic occur when metabolic adaptation, dose ceiling, or caloric creep neutralize GLP-1 effects—here’s how to restart progress.

Ozempic plateau at 3 months happens when metabolic adaptation matches GLP-1 suppression. Here’s how to break through using dose timing, deficit

Weight plateaus at 6 months on Ozempic happen because your body adapts metabolically. Here’s what actually breaks through it—and what doesn’t work.